PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough
Published 05 January 2021
Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has been strongly linked with prostate cancer progression and metastatic potential.
1 Loss of the inhibitory phosphatase, PTEN, leading to hyperactivation of PI3K/AKT/mTOR oncogenic signaling, occurs in 40-50% of metastatic castration-resistant prostate cancer.
1,2 Not surprising is the fact that PTEN loss in patients with metastatic castration-resistant prostate cancer is associated with a worse prognosis and less benefit from androgen receptor (AR) blockade.
3 Likewise, PTEN loss and subsequent Akt activation confer radiation
Daniel Milks, Travel Operator, Owner of MyXOAdventures.com
âAfter I returned from a trip to Cuba last March, my business stopped. Through April, I was doing Instacart deliveries. I knew, If I donât reinvent myself, I am going to die. I had a 15-passenger van I was doing tours in, converted it and set out throughout the United States to every part I wanted to see. I made phone calls to businesses in areas I wanted to visit, asking, âCan I stop by so I can learn about what you do, promote you on social media?â I scheduled national park tripsâthe Badlands, Yosemite, Crater Lake, Canyonlands, Yellowstone. Then I got notice that Costa Rica had opened its borders. I made a beeline back to Florida, to do the same thing there I did here. I made phone calls, sent out emails, people responded, and I created a trip for clients. I filled two Cuba trips for this March, and Iâm opening up a third for February. Things are starting to look brighter.â